Clinical trials: High Risk Medications
Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of…
- Conditions
- Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Trial name
- NCT07724457
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carboplatin
- Volunteers
- 271 people
- Sponsor
- National Cancer Institute (NCI)
Parkinson Disease
Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease
Parkinson disease is a degenerative neurologic condition characterized by slowness of movement, tremor, and loss of balance control. It results in significant degrees of disability for affected individuals.
- Trial name
- NCT00665184
- Testing
- Resistance Exercise via Negative Eccentric Work, Standard care exercise training
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Utah
Musculoskeletal Pain, Neuropathic Pain
Association of High PainDETECT Scores With Pain Region and Diagnosis in Patients Attending a Musculoskeletal and Sports Medicine Clinic
This observational study aims to evaluate the relationship between PainDETECT questionnaire scores, pain regions, and clinical diagnoses in patients presenting to a musculoskeletal and sports medicine clinic.
- Trial name
- PD-MSK (NCT07356115)
- Testing
- No Interventions
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Uskudar University
Tuberculosis
Rifampicin at High Dose for Difficult-to-Treat Tuberculosis
The purpose of this study is to assess the safety of rifampicin given at a dose three times as the standard one, in persons with tuberculosis that belong to groups that have not been widely included in previous trials.
- Trial name
- RIAlta (NCT04768231)
- Testing
- Rifampin
- Where
- 5 sites in Netherlands, Paraguay and 2 more
- Volunteers
- 130 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various…
- Conditions
- Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia
- Trial name
- STOP-NT (NCT01734694)
- Testing
- Vancomycin, Ceftaroline, Daptomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Henry Ford Health System
Coronary Artery Disease
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to…
- Trial name
- PARIS (NCT06321757)
- Testing
- Percutaneous Coronary Intervention with DCB and DAPT
- Where
- 19 sites in Italy, Portugal and 1 more
- Volunteers
- 501 people
- Sponsor
- Fundación EPIC
Healthy Volunteers, Dyslipidaemia
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
The study is testing a new study medicine to treat people with high levels of fat in the blood. The main aim of the study is to see if the new study medicine is safe and how it works in the body.
- Trial name
- NCT05979428
- Testing
- NNC0491-6075
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
High Grade Upper Tract Urothelial Carcinoma
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer.
- Trial name
- NCT02412670
- Testing
- Methotrexate, Vinblastine, Doxorubicin
- Where
- 134 sites in United States
- Volunteers
- 36 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Medication Administered in Error, Antipsychotics and Neuroleptics Toxicity
Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing
This pilot project aims to reduce the prescribing of high-risk medications, such as antipsychotics and benzodiazepines, to hospitalized older adults. To accomplish this, this project consists of two phases.
- Trial name
- NCT04668248
- Testing
- Simulation, Online educational training
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Neoplasms
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
The purpose of this study is to learn more about imaging changes induced by a new therapeutic agent, bevacizumab with the standard steroid, dexamethasone in patients with high grade glioma.
- Trial name
- NCT00769093
- Testing
- Ferumoxytol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Substance Abuse
Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications
Justification and aims of the study: The principal aim of use of opiate substitutes such as methadone or high-dose buprenorphine (HDB) is to reduce the need or the desire to consume the opiate to which the patient is addicted.
- Trial name
- NCT01285856
- Testing
- hair and saliva samples
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
- Trial name
- NCT05950464
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
This Phase 3 study will evaluate whether atirmociclib plus giredestrant improves invasive breast cancer-free survival compared with giredestrant alone in adults with ER-positive, HER2-negative early breast cancer at medium or…
- Trial name
- NCT07890597
- Testing
- Atirmociclib, giredestrant
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
End-stage Renal Disease, Prevention of Thromboembolic Events
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins…
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Trial name
- CONVERT (NCT04523220)
- Testing
- BAY1213790 (Osocimab)
- Where
- 151 sites in United States, Australia and 17 more
- Volunteers
- 704 people
- Sponsor
- Bayer
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
NREM Parasomnias, Sleepwalking
Acoustic Stimulation to Study and Modulate Sleepwalking and Related Arousal Disorders
Disorders of Arousal (DoA)-such as sleepwalking, sleep terrors, and confusional arousals-are common sleep problems that happen during deep, non-dreaming sleep.
- Conditions
- NREM Parasomnias, Sleepwalking, Sleep Terrors, Confusional Arousals
- Trial name
- DoA-CLAS (NCT07754838)
- Testing
- Closed-Loop/Open-Loop Acoustic Stimulation (CLAS)
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Anna Castelnovo
High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG)
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
- Conditions
- High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
- Trial name
- NCT07455045
- Testing
- FZ-AD005
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Malaria Asymptomatic Parasitaemia, Malaria Falciparum
Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections.
- Conditions
- Malaria Asymptomatic Parasitaemia, Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- NCT07389057
- Testing
- DHAP, Single low dose PQ
- Where
- Ghana
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Asthma
Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19
In addition to its impact on health, the COVID-19 pandemic led to increased unemployment and loss of employer-sponsored insurance coverage.
- Trial name
- AFFORD COVID (NCT04613739)
- Testing
- insurance navigation
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Harvard Pilgrim Health Care